Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Food Archives
Print | Email | Share | Comments (0)

Kombiglyze Komes to a Pharmacy Near You


Jan 25, 2011

The kuriously named Kombiglyze XR, a combination of Onglyza (saxagliptin) and the old reliable metformin, has arrived at pharmacies and is available by prescription to people with type 2 diabetes. It's similar to Janumet, an older medication that's a combination of Januvia (sitagliptin) and metformin.

Both sitagliptin and saxagliptin are DPP-4 inhibitors, which means that they inhibit, or temporarily prevent, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption. Unfortunately, GLP-1 is broken down by DPP-4 after only about a minute of beneficial action. Because GLP-1 could lower blood sugar longer if DPP-4 weren't so efficient at destroying it, DPP-4 inhibitors like sitagliptin and saxagliptin come in very handy for people with type 2 diabetes.

When DPP-4 inhibitors are combined with metformin, patients who need both medicines get the convenience of one, rather than two, pills. Apparently it's convenience that is going to be Kombiglyze XR's special forte, as it is taken only once a day, while Janumet is taken twice a day. That may change soon, however, as a New Drug Application (NDA) for an XR form of Janumet has just been accepted for review by the FDA.

Kombiglyze XR, which is made by Bristol-Myers Squibb and AstraZeneca, was approved by the FDA in November 2010.  Janumet is made by Merck and was approved in April 2007. 

Sources:

Merck, Bristol-Myers Squibb, and AstraZeneca

 


Categories: Blood Sugar, Diabetes, Diabetes, Food, Insulin, Medications, Medications Research, Metformin, Onglyza, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.